For this purpose, we utilized a dosing regime consisting of five consecutive daily intraperitoneal (i.p.)injections of 1 μg antibody-complexed IL-2 or IL-2-Fc molar equivalent starting 1 day after subcutaneous injection of tumour cells. This evidence concerns the gene IL2 and neoplasm.